AR and neoplasm: As in previous experiments with P3CA parental cells (Figure 3a), enzalutamide monotherapy did not show a significant impact on P3CA-AR-V7 tumor growth, nor did enzalutamide monotherapy enable P3CA-Empty tumors to avoid rejection (Figure S6).